Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes

被引：0

作者：

Koon, Alexis ^{[1
]}

He, Jiaxian ^{[2
]}

Patel, Jai ^{[3
]}

Morse, Allison ^{[4
]}

Boseman, Victoria ^{[5
]}

Hamilton, Alicia ^{[6
]}

Knight, Thomas ^{[7
]}

Shah, Nilay ^{[7
]}

Ragon, Brittany ^{[7
]}

Chojecki, Aleksander ^{[7
]}

Ai, Jing ^{[7
]}

Steuerwald, Nury ^{[6
]}

Gerber, Jonathan ^{[8
]}

Copelan, Edward ^{[7
]}

Grunwald, Michael ^{[7
]}

Arnall, Justin ^{[9
]}

机构：

[1] Rosalind Franklin Univ Med & Sci, Coll Pharm, N Chicago, IL 60064 USA

[2] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Clin Trials & Evidence Synth, Baltimore, MD 21205 USA

[3] Atrium Hlth, Levine Canc Inst, Dept Canc Pharmacol, Charlotte, NC 28204 USA

[4] Atrium Hlth, Levine Canc Inst, Dept Pharm, Charlotte, NC 28204 USA

[5] Atrium Hlth, Levine Canc Inst, Dept Biostat & Data Sci, Charlotte, NC 28204 USA

[6] Atrium Hlth, Mol Biol Core Lab, Levine Canc Inst, Charlotte, NC 28204 USA

[7] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC 28204 USA

[8] UMass Mem Med Ctr, Div Hematol Oncol, Worcester, MA 01655 USA

[9] Atrium Hlth, Specialty Pharm Serv, Charlotte 28204, NC USA

来源：

PHARMACOGENOMICS | 2023年 / 24卷 / 15期

关键词：

allogeneic hematopoietic stem cell transplant; hematopoietic stem cell transplant; pentamidine; Pneumocystis jirovecii pneumonia; PNEUMOCYSTIS-JIROVECI PNEUMONIA; CELL TRANSPLANTATION; PJP PROPHYLAXIS;

D O I：

10.2217/pgs-2023-0093

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Intravenous pentamidine is used for prophylaxis against Pneumocystis jirovecii pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by CYP2C19, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as P. jirovecii pneumonia prophylaxis. The primary objective was the association between CYP2C19 phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (N = 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (p = 0.18) or discontinuation due to side effects (p = 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475). Drug discontinuation rates and P. jirovecii pneumonia infection rates were low.

引用

页码：821 / 830

页数：10

共 50 条

[31] Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Li-Wan-Po, Alain
Girard, Thierry
Farndon, Peter
Cooley, Candy
Lithgow, James
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (03) : 222 - 230
[32] The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia
Rodrigues-Silva, Christielly
Semedo, Agostinho Tavares
da Silva Neri, Hiasmin Franciely
Vianello, Rosana Pereira
Galaviz-Hernandez, Carlos
Sosa-Macias, Martha
de Brito, Rodrigo Bernini
Ghedini, Paulo Cesar
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 427 - 432
[33] Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study
Mahajna, Mahmood
Abu Fanne, Rami
Berkovitch, Matitiahu
Tannous, Elias
Vinker, Shlomo
Green, Ilan
Matok, Ilan
BIOMEDICINES, 2023, 11 (12)
[34] Association Between CYP2C19 Polymorphism and Depressive Symptoms
Sim, Sarah C.
Nordin, Linn
Andersson, Therese M. -L.
Virding, Susanne
Olsson, Marita
Pedersen, Nancy L.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2010, 153B (06) : 1160 - 1166
[35] Distribution of CYP2C19☆2 and CYP2C19☆3 polymorphisms in Venezuelan populations with different admixture
Castro de Guerra, Dinorah
Flores, Sara
Helen Izaguirre, Mary
ANNALS OF HUMAN BIOLOGY, 2013, 40 (02) : 197 - 200
[36] The efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism
Chen, MC
Hu, CT
Wang, LY
Lin, HH
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (03) : 274 - 275
[37] Association between blood carisoprodol:: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers:: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?
Bramness, JG
Skurtveit, S
Fauske, L
Grung, M
Molven, A
Morland, J
Steen, VM
PHARMACOGENETICS, 2003, 13 (07): : 383 - 388
[38] PharmVar GeneFocus: CYP2C19
Botton, Mariana R.
Whirl-Carrillo, Michelle
Del Tredici, Andria L.
Sangkuhl, Katrin
Cavallari, Larisa H.
Agundez, Jose A. G.
Duconge, Jorge
Lee, Ming Ta Michael
Woodahl, Erica L.
Claudio-Campos, Karla
Daly, Ann K.
Klein, Teri E.
Pratt, Victoria M.
Scott, Stuart A.
Gaedigk, Andrea
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) : 352 - 366
[39] The CYP2C19 enzyme polymorphism
Wedlund, PJ
PHARMACOLOGY, 2000, 61 (03) : 174 - 183
[40] The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19☆35 and CYP2C19☆2 Alleles
Chaudhry, Amarjit S.
Prasad, Bhagwat
Shirasaka, Yoshiyuki
Fohner, Alison
Finkelstein, David
Fan, Yiping
Wang, Shuoguo
Wu, Gang
Aklillu, Eleni
Sim, Sarah C.
Thummel, Kenneth E.
Schuetz, Erin G.
DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1226 - 1235

← 1 2 3 4 5 →